Gastrointestinal blood loss on phenylbutazone and feprazone.
Feprazone, a new anti-inflammatory drug, is a useful antirheumatic preparation which causes little gastrointestinal upset. This short cross-over study shows no significant gastrointestinal blood loss with either feprazone or phenylbutazone by the red-cell chromium-51 labelling method.
D001168:Arthritis / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001416:Back Pain / Q000188:drug therapy; D002860:Chromium Radioisotopes; D005243:Feces / Q000032:analysis; D005260:Female; D011298:Feprazone / Q000009:adverse effects* / Q000627:therapeutic use; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008297:Male; D010653:Phenylbutazone / Q000009:adverse effects* / Q000031:analogs & derivatives*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy
D002860:Chromium Radioisotopes; D011298:Feprazone; D010653:Phenylbutazone